Basal Insulin Dose Adjustment for Elevated Fasting Glucose
Increase the Lantus dose by 2 units every 3 days until the fasting glucose reaches the target of 80-130 mg/dL (4.4-7.2 mmol/L), using an evidence-based titration algorithm. 1
Recommended Titration Algorithm
The 2025 ADA Standards of Care provides a clear, evidence-based approach for basal insulin titration 1:
Increase by 2 units every 3 days based on fasting plasma glucose (FPG):
- FPG <4.4 mmol/L (<79 mg/dL): Decrease by 2 units
- FPG 4.4-7.0 mmol/L (79-126 mg/dL): No change
- FPG 7.1-10.0 mmol/L (127-180 mg/dL): Increase by 2 units
- FPG >10.0 mmol/L (>180 mg/dL): Increase by 4 units
With a current fasting glucose of 215 mg/dL (11.9 mmol/L), increase the dose by 4 units immediately (from 30 to 34 units), then continue titrating every 3 days using this algorithm until target is reached 1.
Alternative Patient-Managed Titration
If the patient is capable of self-management, a more aggressive approach can be used: increase by 2 units every 3 days continuously until FPG reaches 5.5 mmol/L (100 mg/dL), as long as no hypoglycemia occurs 2. This patient-managed approach has been shown to achieve greater HbA1c reductions (-1.22% vs -1.08%) compared to clinic-managed titration 2.
Key Safety Considerations
- Monitor for hypoglycemia: If blood glucose drops below 4.0 mmol/L (72 mg/dL) without clear cause, reduce the dose by 10-20% 1
- Expected final dose: Most patients require 40-70 units/day to achieve glycemic targets, with approximately 50% reaching HbA1c ≤7% 3
- Titration should be prophylactic and regular, not reactive—adjust every 3 days based on the pattern, not individual readings 1
Common Pitfalls to Avoid
Therapeutic inertia is the primary barrier to achieving glycemic control. The FDA label emphasizes that dose adjustments must occur under medical supervision with appropriate glucose monitoring 4, but this should not delay necessary titration. The evidence strongly supports systematic, algorithm-based titration rather than waiting for clinic visits 1, 2.
Do not under-titrate: With FPG of 215 mg/dL, this patient is significantly above target and requires prompt dose escalation. The Treat-to-Target trial demonstrated that systematic titration to FPG <100 mg/dL is both safe and effective, with 60% of patients achieving HbA1c ≤7% 5.